White House Reviews 340B Rebate Rule
The White House has completed its initial regulatory review of a new Department of Health and Human Services proposal regarding 340B drug pricing program rebates. The review signals continued federal focus on data transparency and standardized reporting in healthcare pricing. Informatics teams may be impacted by new reporting mandates stemming from such regulations.
- The 340B Drug Pricing Program was created by the Veterans Health Care Act of 1992 to allow certain hospitals and clinics that serve low-income populations to purchase outpatient drugs at a discounted price. The stated purpose is to permit these "covered entities" to "stretch scarce federal resources as far as possible." - A central conflict in the 340B program involves pharmaceutical manufacturers restricting discounts for drugs dispensed through contract pharmacies. Manufacturers argue these restrictions are necessary to prevent providing a 340B discount and a Medicaid rebate on the same drug, a prohibited practice known as a "duplicate discount." - In response to disputes, the Health Resources and Services Administration (HRSA) finalized a new Administrative Dispute Resolution (ADR) process in April 2024. This creates a formal mechanism for covered entities to file claims of overcharging and for manufacturers to address alleged violations of program rules. - The new HHS proposal involves a shift from upfront discounts to a post-purchase rebate model for certain drugs. Under this model, hospitals would pay the full price for a drug, then submit claims data to a third-party vendor to receive a rebate from the manufacturer. - This rebate model has faced significant legal challenges. In February 2026, the U.S. District Court for the District of Maine vacated HHS's approval of a rebate pilot program, sending it back to the agency for reconsideration. - Following the court ruling, HRSA issued a Request for Information (RFI) in February 2026, seeking input from hospitals and other stakeholders on the potential impact of a rebate model on administrative costs, staffing, and cash flow. - For a nursing informaticist, these changes directly impact EHR systems like Epic, which must accurately identify 340B-eligible patients and transactions, manage complex claims data submissions for rebates, and ensure auditable compliance to avoid diversion or duplicate discount penalties. This requires robust data infrastructure and specialized reporting capabilities within the health IT system.
